Cargando…

Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma

BACKGROUND: As epidermal growth factor receptor (EGFR) is involved in the pathogenesis of malignant pleural mesotheliomas (MPMs), the anti-EGFR drugs may be effective in treating MPM patients. Mutations of the EGFR gene or its downstream effectors may cause constitutive activation leading to cell pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mezzapelle, R, Miglio, U, Rena, O, Paganotti, A, Allegrini, S, Antona, J, Molinari, F, Frattini, M, Monga, G, Alabiso, O, Boldorini, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668472/ https://www.ncbi.nlm.nih.gov/pubmed/23558893 http://dx.doi.org/10.1038/bjc.2013.130

Ejemplares similares

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma
por: Linton, A, et al.
Publicado: (2014)

Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2017)

GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi
por: Vader, M J C, et al.
Publicado: (2017)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients
por: Bai, Yiyang, et al.
Publicado: (2020)

Novel circulating tumor cell-detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma
por: Kanayama, Masatoshi, et al.
Publicado: (2021)

A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies
por: Jensen, Steffen Grann, et al.
Publicado: (2021)

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
por: Kuan, Feng-Che, et al.
Publicado: (2015)

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
por: Molinari, F, et al.
Publicado: (2009)

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
por: Pinato, D J, et al.
Publicado: (2013)

Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report
por: Pezzuto, Federica, et al.
Publicado: (2021)

Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma
por: Zhang, Yuan, et al.
Publicado: (2022)

Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors
por: Weber, F, et al.
Publicado: (2005)

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
por: Boeck, S, et al.
Publicado: (2013)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing
por: Patton, S, et al.
Publicado: (2014)

Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus
por: Tomlinson, V A L, et al.
Publicado: (2007)

Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer
por: Wang, Chen, et al.
Publicado: (2016)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
por: Cedres, Susana, et al.
Publicado: (2021)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Associations of mRNA:microRNA for the Shared Downstream Molecules of EGFR and Alternative Tyrosine Kinase Receptors in Non-small Cell Lung Cancer
por: Wang, Fengfeng, et al.
Publicado: (2016)

Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile
por: Graham, K, et al.
Publicado: (2010)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Rethought histologic classification of pleural mesothelioma to better treat: go forward from looking back
por: Astoul, Philippe
Publicado: (2020)

Sequential multi-parametric MRI in assessment of the histological subtype and features in the malignant pleural mesothelioma xenografts
por: Zhang, Zhenghua, et al.
Publicado: (2023)

NFE2L3 as a Novel Biomarker Associated With IL-2/STAT5/NLRP3 Signaling Pathway in Malignant Pleural Mesothelioma and Other Cancers
por: Wang, Zhen, et al.
Publicado: (2022)

High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer
por: Kim, D-W, et al.
Publicado: (2008)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
por: Treasure, Tom, et al.
Publicado: (2011)

Robust partitioning of microRNA targets from downstream regulatory changes
por: Patel, Ravi K, et al.
Publicado: (2020)

Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
por: Affatato, Roberta, et al.
Publicado: (2020)

Malignant Pleural Mesothelioma Nodal Status: Where Are We at?
por: Ricciardi, Sara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2f81jujrqjb10gnkb8alb2v5a2